Ligand ID: 8NU


Drugbank ID:
DB00734
(Risperidone)


Indication:
For the treatment of schizophrenia in adults and in adolescents, ages 13 to 17, and for the short-term treatment of manic or mixed episodes of bipolar I disorder in children and adolescents ages 10 to 17. May also be used to manage symptoms of inappropriate behavior due to aggression and/or psychosis in patients with severe dementia.

Get human targets for 8NU in PDB (known and potential targets)

RESULTS FROM SUB-STRUCTURAL SIMILARITY SEARCHES MAPPED TO LIGAND '8NU'

Click here for results that match SARS-Cov-2 / COVID-19 structures only
Click here for results that match SARS-related structures only


1) User may click on the DrReposER ID (the second column) to get information on the binding sites and drug molecule.
2) Click View (the second last column) to view matched residues and superposition in the NGL viewer (upper right part).
3) User may also click on the Dock (the last column) to get script for molecular docking in UCSF Chimera through AutoDock Vina.

DrReposER ID / Desc. Hit
PDBID		 Hit
Macromolecule		 Res.
Matches		 View Interface RMSD Seq.
Identity (%)		 HETATM Dock
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_A_8NUA3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		1z1j 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
SER A 254
ILE A 281
LEU A 262
LEU A 242
TYR A 209
1.58A20.98
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6CM4_A_8NUA2001_1
(D(2) DOPAMINE
RECEPTOR, ENDOLYSIN
CHIMERA)		2ahm REPLICASE
POLYPROTEIN 1AB,
HEAVY CHAIN
(SARSr-CoV)		4 / 4
ASP H  55
ALA H  21
SER H  16
PHE H  11
1.51A18.50
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		2ajf SPIKE PROTEIN
(SARSr-CoV)		5 / 12
SER E 386
VAL E 382
LEU E 421
PHE E 325
VAL E 328
1.48A18.45
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_A_8NUA3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		2c3s 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
SER A 254
ILE A 281
LEU A 262
LEU A 242
TYR A 209
1.66A20.98
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_A_8NUA3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		2cjr NUCLEOCAPSID PROTEIN
(SARS-COV
TW1)		5 / 12
SER C 319
SER D 311
PHE C 275
PHE D 316
LEU D 332
1.55A13.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_1
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		2cjr NUCLEOCAPSID PROTEIN
(SARS-COV
TW1)		4 / 5
ASP D 289
ILE C 321
PHE C 316
TYR D 299
1.41A13.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		2d2d 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
THR B  35
LEU B 115
PHE B 159
PHE B 103
VAL B 157
1.53A21.48
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		2dd8 IGG HEAVY CHAIN
IGG LIGHT CHAIN
(Homo
sapiens)		6 / 12
SER L 181
VAL H 142
SER H 179
LEU H 175
LEU H 170
VAL H 169
1.75A20.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		2gdt LEADER PROTEIN
P65 HOMOLOG
NSP1
(SARSr-CoV)		5 / 12
VAL A 100
THR A  39
PHE A  20
LEU A  53
VAL A  43
1.54A16.22
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		2ghw SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
TYR A 356
VAL A 349
SER A 380
PHE A 325
LEU A 355
1.49A22.19
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_1
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		2gib NUCLEOCAPSID PROTEIN
(SARSr-CoV)		4 / 5
ASP A 289
ILE B 321
PHE B 316
TYR A 299
1.42A12.23
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6CM4_A_8NUA2001_0
(D(2) DOPAMINE
RECEPTOR, ENDOLYSIN
CHIMERA)		2gt8 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
VAL A 171
THR A 135
PHE A 112
PHE A 140
TYR A 118
1.78A20.28
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		2h85 PUTATIVE ORF1AB
POLYPROTEIN
(SARSr-CoV)		5 / 12
TYR A 225
VAL A 338
PHE A 302
LEU A 299
VAL A 303
1.52A23.13
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_A_8NUA3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		2qc2 3C-LIKE PROTEINASE
(-)		5 / 12
SER A 254
ILE A 281
LEU A 262
LEU A 242
TYR A 209
1.68A20.60
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		2qc2 3C-LIKE PROTEINASE
(-)		5 / 12
THR B  35
LEU B 115
PHE B 159
PHE B 103
VAL B 157
1.55A20.60
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		2rhb URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARSr-CoV)		5 / 12
TYR D 225
VAL D 338
PHE D 302
LEU D 299
VAL D 303
1.56A23.52
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6CM4_A_8NUA2001_0
(D(2) DOPAMINE
RECEPTOR, ENDOLYSIN
CHIMERA)		2rhb URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARSr-CoV)		5 / 12
PHE A 176
VAL A 172
THR C 285
SER C 288
TYR A  88
1.56A20.79
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_A_8NUA3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		3atw 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
SER B 254
ILE B 281
LEU B 262
LEU B 242
TYR B 209
1.69A21.24
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		3bgf SPIKE PROTEIN S1
(SARSr-CoV)		5 / 12
SER S 386
VAL S 382
LEU S 421
PHE S 325
VAL S 328
1.41A19.73
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_1
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		3d0g ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		4 / 5
ASP B 382
PHE B 390
ASN B 397
TYR B 385
1.25A20.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_A_8NUA3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		3d0i ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		5 / 12
THR B 371
LEU B 558
PHE B 369
PHE B 315
LEU B 320
1.64A20.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		3ea7 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
THR B  35
LEU B 115
PHE B 159
PHE B 103
VAL B 157
1.55A20.98
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		3ea9 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
THR A  35
LEU A 115
PHE A 159
PHE A 103
VAL A 157
1.54A20.98
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_A_8NUA3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		3f9e 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
SER A 254
ILE A 281
LEU A 262
LEU A 242
TYR A 209
1.66A20.60
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_A_8NUA3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		3m3s 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
THR B 190
LEU B  27
PHE B 181
LEU B  86
TYR B  54
1.71A20.98
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		3m3v 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
THR B  35
LEU B 115
PHE B 159
PHE B 103
VAL B 157
1.54A20.60
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6CM4_A_8NUA2001_1
(D(2) DOPAMINE
RECEPTOR, ENDOLYSIN
CHIMERA)		3sci ACE2
(Homo
sapiens)		4 / 4
ASP B  38
ALA B  46
SER B  44
PHE B  72
1.50A21.75
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		3scj SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
SER F 386
VAL F 382
LEU F 421
PHE F 325
VAL F 328
1.54A17.52
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_A_8NUA3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		3scl ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		5 / 12
SER B 124
THR B 125
ILE B 126
LEU B 359
TYR B 510
1.68A20.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_1
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		3scl ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		4 / 5
ASP B 382
PHE B 390
ASN B 397
TYR B 385
1.32A20.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6CM4_A_8NUA2001_0
(D(2) DOPAMINE
RECEPTOR, ENDOLYSIN
CHIMERA)		3scl SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
VAL E 328
SER E 386
PHE E 361
TRP E 423
THR E 425
1.76A16.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6CM4_A_8NUA2001_1
(D(2) DOPAMINE
RECEPTOR, ENDOLYSIN
CHIMERA)		3scl ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		4 / 4
ASP B 367
ALA B 413
SER B 409
PHE B 274
1.78A23.18
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_A_8NUA3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		3sna 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
SER A 254
ILE A 281
LEU A 262
LEU A 242
TYR A 209
1.60A21.26
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		3vb6 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
THR B  35
LEU B 115
PHE B 159
PHE B 103
VAL B 157
1.54A20.98
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_A_8NUA3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		4hi3 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
SER A 254
ILE A 281
LEU A 262
LEU A 242
TYR A 209
1.64A20.16
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		4ow0 PAPAIN-LIKE PROTEASE
(SARS-COV
Urbani)		5 / 12
SER A  86
TYR A  36
THR A 169
PHE A  80
LEU A  81
1.33A22.19
DMS  B 903 (-2.6A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		5b6o 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
THR A  35
LEU A 115
PHE A 159
PHE A 103
VAL A 157
1.55A20.73
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		5e6j REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)		5 / 12
SER A 246
THR A 302
PHE A 305
LEU A 179
VAL A 206
1.53A22.14
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_A_8NUA3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
SER A 254
ILE A 281
LEU A 262
LEU A 242
TYR A 209
1.72A16.71
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		5tl6 REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)		5 / 12
SER B  86
TYR B  36
THR B 169
PHE B  80
LEU B  81
1.44A22.19
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		5wrg SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
TYR A 367
VAL A 328
TRP A 423
PHE A 361
PHE A 360
1.48A15.37
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_A_8NUA3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		5x29 ENVELOPE SMALL
MEMBRANE PROTEIN
(SARSr-CoV)		5 / 12
THR C  30
ILE C  33
LEU C  21
PHE B  23
LEU B  19
1.43A14.36
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_A_8NUA3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		5x4r S PROTEIN
(MERS-CoV)		5 / 12
ILE A 256
LEU A 273
PHE A 147
LEU A 251
TYR A 144
1.56A19.23
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_1
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		5x4r S PROTEIN
(MERS-CoV)		4 / 5
ASP A  83
ILE A 256
ASN A 104
TYR A  85
1.45A19.23
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6CM4_A_8NUA2001_0
(D(2) DOPAMINE
RECEPTOR, ENDOLYSIN
CHIMERA)		5x5b SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		5 / 12
PHE C 361
TRP C 423
PHE C 334
TYR C 438
THR C 425
1.71A17.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_1
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		5x5b SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		4 / 5
ASP B 976
ILE A 955
ASN B 721
TYR B 738
1.03A15.61
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		5x5b SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		5 / 12
TYR B 356
VAL B 510
THR B 509
LEU B 355
PHE B 501
1.50A15.61
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_1
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		5x5c S PROTEIN
(MERS-CoV)		4 / 5
ASP B  83
ILE B 256
ASN B 104
TYR B  85
1.45A14.58
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		5x5f S PROTEIN
(MERS-CoV)		5 / 12
SER C 684
THR C 685
PHE C 674
LEU C 759
VAL C 711
1.34A14.58
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_A_8NUA3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		5x5f S PROTEIN
(MERS-CoV)		5 / 12
SER B 829
ILE A 333
LEU A 347
PHE A 327
PHE A 354
1.45A14.58
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_A_8NUA3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		5xlr SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
THR B 425
LEU B 499
PHE B 361
PHE B 360
LEU B 355
1.47A15.37
THR  B 425 ( 0.8A)
LEU  B 499 ( 0.6A)
PHE  B 361 ( 1.3A)
PHE  B 360 ( 1.3A)
LEU  B 355 ( 0.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		5y3e REPLICASE
POLYPROTEIN 1A
(SARSr-CoV)		5 / 12
SER A 246
THR A 302
PHE A 305
LEU A 179
VAL A 206
1.55A22.63
None
GOL  A 408 (-3.6A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_A_8NUA3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6acg ACE2
(Homo
sapiens)		5 / 12
THR D 371
LEU D 529
PHE D 308
PHE D 315
LEU D 320
1.57A20.61
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_A_8NUA3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6acg SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
ILE A 428
TRP A 423
PHE A 361
PHE A 360
LEU A 355
1.50A15.37
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_1
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6acg SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 5
ASP A  57
ILE A  87
PHE A  83
ASN B 505
1.29A15.37
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6CM4_A_8NUA2001_1
(D(2) DOPAMINE
RECEPTOR, ENDOLYSIN
CHIMERA)		6acg SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 4
ASP C 154
ALA C 127
SER C 113
PHE C 157
1.52A17.90
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_1
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6acj ACE2
(Homo
sapiens)		4 / 5
ASP D 382
PHE D 390
ASN D 397
TYR D 385
1.25A20.61
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6CM4_A_8NUA2001_0
(D(2) DOPAMINE
RECEPTOR, ENDOLYSIN
CHIMERA)		6ack SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
THR A 236
SER A 239
PHE A  76
PHE A  22
THR A  20
1.62A17.90
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6ack SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
VAL A 349
THR A 320
LEU A 374
LEU A 499
VAL A 382
1.22A15.37
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_1
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6crx SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		4 / 5
ASP A 277
ILE A 272
PHE A 213
ASN A  65
1.44A15.88
None
None
None
NAG  A1301 (-1.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_A_8NUA3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6crx SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
SER C 248
THR C  71
ILE C  72
LEU C 170
PHE C 179
1.60A15.88
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6CM4_A_8NUA2001_1
(D(2) DOPAMINE
RECEPTOR, ENDOLYSIN
CHIMERA)		6crx SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		4 / 4
ASP B  23
ALA B 139
SER B 239
PHE B  76
1.67A17.64
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6CM4_A_8NUA2001_0
(D(2) DOPAMINE
RECEPTOR, ENDOLYSIN
CHIMERA)		6crz SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
VAL B1015
THR B 863
PHE B 880
PHE B1034
THR B1048
1.68A17.64
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6CM4_A_8NUA2001_1
(D(2) DOPAMINE
RECEPTOR, ENDOLYSIN
CHIMERA)		6cs2 ACE2
(Homo
sapiens)		4 / 4
ASP D 367
ALA D 412
SER D 409
PHE D 438
1.28A22.00
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6cs2 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
SER B 386
VAL B 382
LEU B 421
PHE B 325
VAL B 328
1.37A15.88
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6lze VIRAL PROTEASE
(SARS-CoV-2)		5 / 12
VAL A  20
THR A  21
LEU A  32
LEU A 177
VAL A  86
1.79A20.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6lze VIRAL PROTEASE
(SARS-CoV-2)		5 / 12
VAL A  20
THR A  26
LEU A  32
LEU A 177
VAL A  86
1.68A20.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6m03 MAIN PROTEASE
(SARS-CoV-2)		5 / 12
SER A  81
VAL A  20
THR A  26
LEU A 177
VAL A  86
1.43A20.77
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_1
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6m17 ACE2
(Homo
sapiens)		4 / 5
ASP B 382
PHE B  40
ASN B 397
TYR B 385
1.36A18.91
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_A_8NUA3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6m17 ACE2
(Homo
sapiens)		5 / 12
THR B 371
LEU B 558
PHE B 369
PHE B 315
LEU B 320
1.68A18.91
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_A_8NUA3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6m17 SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)		5 / 12
SER A 323
THR A 396
LEU A 234
PHE A 420
PHE A 421
1.65A19.44
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6m17 SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)		6 / 12
SER A 430
VAL A 232
THR A 235
LEU A  43
LEU A  46
VAL A  50
1.70A19.44
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6CM4_A_8NUA2001_0
(D(2) DOPAMINE
RECEPTOR, ENDOLYSIN
CHIMERA)		6m1d SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)		5 / 12
TRP C 205
VAL C 439
SER C 122
PHE C 289
PHE C  48
1.72A21.17
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 12
SER B 284
TRP B 207
VAL B 212
THR B 304
LEU B 271
1.77A20.77
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_A_8NUA3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 12
SER A 254
ILE A 281
LEU A 262
LEU A 242
TYR A 209
1.77A20.77
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_A_8NUA3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 12
SER B 254
ILE B 281
LEU B 262
LEU B 242
TYR B 209
1.77A20.77
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_A_8NUA3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 12
SER D 254
ILE D 281
LEU D 262
LEU D 242
TYR D 209
1.75A20.77
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_A_8NUA3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 12
SER C 254
ILE C 281
LEU C 262
LEU C 242
TYR C 209
1.78A20.77
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_A_8NUA3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6m2q 3CL PROTEASE
(SARS-CoV-2)		5 / 12
SER A 254
ILE A 281
LEU A 262
LEU A 242
TYR A 209
1.74A20.77
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_A_8NUA3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6m71 NSP12
(SARS-CoV-2)		5 / 12
SER A 318
THR A 319
LEU A 308
PHE A 326
LEU A 655
1.60A18.87
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6m71 NSP12
(SARS-CoV-2)		5 / 12
VAL A 315
SER A 318
THR A 319
LEU A 308
LEU A 655
1.63A18.87
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6nb6 SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
TYR A 367
VAL A 328
TRP A 423
PHE A 361
PHE A 360
1.37A14.70
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6nur NSP12
(SARSr-CoV)		5 / 12
VAL A 315
SER A 318
THR A 319
LEU A 308
LEU A 655
1.49A17.75
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_A_8NUA3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6nus NSP12
(SARSr-CoV)		5 / 12
SER A 709
ILE A 696
LEU A 775
PHE A 745
LEU A 723
1.49A17.75
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_A_8NUA3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
THR A 240
ILE A 101
LEU A 229
PHE A 175
PHE A 192
1.68A14.83
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
TYR A 369
VAL A 524
THR A 523
LEU A 368
PHE A 515
1.52A14.83
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_1
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6vw1 ACE2
(Homo
sapiens)		4 / 5
ASP A 382
PHE A 390
ASN A 397
TYR A 385
1.32A20.61
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_A_8NUA3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6vw1 ACE2
(Homo
sapiens)		5 / 12
THR B 371
LEU B 558
PHE B 369
PHE B 315
LEU B 320
1.66A20.61
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6vww URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 12
TYR A 226
VAL A 339
PHE A 303
LEU A 300
VAL A 304
1.55A21.67
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
TYR B 369
VAL B 524
THR B 523
LEU B 368
PHE B 515
1.52A14.96
None
None
None
NAG  B1307 (-4.9A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
TYR A 369
VAL A 524
THR A 523
LEU A 368
PHE A 515
1.54A14.96
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6w41 CR3022 FAB HEAVY
CHAIN
CR3022 FAB LIGHT
CHAIN
(Homo
sapiens)		5 / 12
VAL H 169
SER H 177
LEU L 175
LEU L 135
VAL L 133
1.60A15.22
GOL  L 301 (-4.5A)
GOL  L 301 (-3.1A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_1
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6w41 SPIKE PROTEIN S1
(SARS-CoV-2)		4 / 5
ASP C 364
ILE C 434
PHE C 342
ASN C 334
1.64A17.24
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_1
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6w41 CR3022 FAB HEAVY
CHAIN
SPIKE PROTEIN S1
(Homo
sapiens;
SARS-CoV-2)		4 / 5
ASP H  54
ILE H  34
PHE H  29
ASN C 437
1.80A15.22
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_1
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6w41 SPIKE PROTEIN S1
(SARS-CoV-2)		4 / 5
ILE C 410
PHE C 400
ASN C 501
TYR C 495
1.74A17.24
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6w41 CR3022 FAB LIGHT
CHAIN
(Homo
sapiens)		5 / 12
SER L 159
VAL L 163
THR L 164
PHE L 139
VAL L 146
1.62A17.02
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6w41 CR3022 FAB LIGHT
CHAIN
(Homo
sapiens)		5 / 12
SER L  93
TYR L  96
LEU L   4
LEU L  33
VAL L  27
1.70A17.02
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6w41 SPIKE PROTEIN S1
(SARS-CoV-2)		5 / 12
TRP C 436
PHE C 342
PHE C 374
LEU C 513
VAL C 511
1.75A17.24
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_1
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6w41 CR3022 FAB HEAVY
CHAIN
SPIKE PROTEIN S1
(Homo
sapiens;
SARS-CoV-2)		4 / 5
ASP H 101
ILE H  98
ASN C 370
TYR H  32
1.70A15.22
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6w41 CR3022 FAB HEAVY
CHAIN
CR3022 FAB LIGHT
CHAIN
(Homo
sapiens)		5 / 12
SER H 180
THR L 172
LEU H 138
LEU H 159
VAL H 163
1.76A15.22
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_A_8NUA3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6w41 CR3022 FAB HEAVY
CHAIN
CR3022 FAB LIGHT
CHAIN
(Homo
sapiens)		5 / 12
SER H 130
THR H 131
PHE L 118
PHE L 116
LEU H 124
1.74A15.22
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_1
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 5
ASP A6923
ILE A6955
PHE A6985
ASN A6853
1.76A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_A_8NUA3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6w63 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
SER A 254
ILE A 281
LEU A 262
LEU A 242
TYR A 209
1.78A20.77
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6w6y NSP3
(SARS-CoV-2)		5 / 12
TYR A  42
VAL A  49
LEU A  43
LEU A  75
VAL A  96
1.74A
None
AMP  A 201 ( 3.7A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6w6y NSP3
(SARS-CoV-2)		5 / 12
TYR B  42
VAL B  49
LEU B  43
LEU B  75
VAL B  96
1.69A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_1
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6w75 NSP16
(SARS-CoV-2)		4 / 5
ASP A6923
ILE A6955
PHE A6985
ASN A6853
1.75A20.00
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_1
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6w75 NSP16
(SARS-CoV-2)		4 / 5
ASP C6923
ILE C6955
PHE C6985
ASN C6853
1.79A20.00
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		5 / 12
SER C 245
THR C 301
LEU C 172
PHE C 304
LEU C 125
1.74A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		5 / 12
SER A 245
THR A 301
PHE A 304
LEU A 178
VAL A 205
1.51A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		5 / 12
SER B 239
VAL B 235
THR B 312
LEU B 199
PHE B 216
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		5 / 12
SER B 245
THR B 301
PHE B 304
LEU B 178
VAL B 205
1.49A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		5 / 12
SER C 239
VAL C 235
THR C 312
LEU C 199
PHE C 216
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		5 / 12
SER A 170
THR A 168
PHE A 241
PHE A 304
VAL A 205
1.65A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		5 / 12
SER A 239
VAL A 235
THR A 312
LEU A 199
PHE A 216
1.70A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		5 / 12
SER C 245
THR C 301
PHE C 304
LEU C 178
VAL C 205
1.49A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6wcf NSP3
(SARS-CoV-2)		5 / 12
TYR A  42
VAL A  49
LEU A  43
LEU A  75
VAL A  96
1.70A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6wey NSP3
(SARS-CoV-2)		5 / 12
TYR A 246
VAL A 253
LEU A 247
LEU A 279
VAL A 300
1.69A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_1
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 5
ASP D 288
ILE C 320
PHE C 315
TYR D 298
1.39A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_1
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 5
ASP F 288
ILE E 320
PHE E 315
TYR F 298
1.45A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_1
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 5
ASP A 288
ILE B 320
PHE B 315
TYR A 298
1.46A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_1
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 5
ASP B 288
ILE A 320
PHE A 315
TYR B 298
1.41A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_1
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 5
ASP C 288
ILE D 320
PHE D 315
TYR C 298
1.46A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_1
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 5
ASP C6923
ILE C6955
PHE C6985
ASN C6853
1.77A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_1
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 5
ASP A6923
ILE A6955
PHE A6985
ASN A6853
1.73A
None
None
None
FMT  A7107 (-3.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
THR B  76
LEU B 113
PHE B 110
PHE B  53
VAL B 133
1.62A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_1
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6wkq NSP16
(SARS-CoV-2)		4 / 5
ASP C6923
ILE C6955
PHE C6985
ASN C6853
1.77A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_1
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6wkq NSP16
(SARS-CoV-2)		4 / 5
ASP A6923
ILE A6955
PHE A6985
ASN A6853
1.74A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 12
TYR A 226
VAL A 339
PHE A 303
LEU A 300
VAL A 304
1.52A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_1
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 5
ASP A 324
ILE A 306
PHE A 330
ASN A 200
1.78A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_1
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 5
ASP B 324
ILE B 306
PHE B 330
ASN B 200
1.77A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 12
TYR B 226
VAL B 339
PHE B 303
LEU B 300
VAL B 304
1.53A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_A_8NUA3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6wnp 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
SER A 254
ILE A 281
LEU A 262
LEU A 242
TYR A 209
1.77A20.77
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6wnp 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
VAL A  20
THR A  26
LEU A  32
LEU A 177
VAL A  86
1.66A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6wnp 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
VAL A  20
THR A  21
LEU A  32
LEU A 177
VAL A  86
1.79A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
TYR A  42
VAL A  49
LEU A  43
LEU A  75
VAL A  96
1.70A
None
APR  A 201 (-3.8A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
TYR D  42
VAL D  49
LEU D  43
LEU D  75
VAL D  96
1.67A
None
APR  D 201 (-3.6A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
TYR C  42
VAL C  49
LEU C  43
LEU C  75
VAL C  96
1.66A
None
APR  C 201 (-3.8A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_1
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 5
ILE B 131
PHE B 132
ASN B  72
TYR B  42
1.78A
APR  B 201 (-3.3A)
APR  B 201 (-3.6A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
TYR B  42
VAL B  49
LEU B  43
LEU B  75
VAL B  96
1.71A
None
APR  B 201 (-3.7A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_1
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 5
ASP A6923
ILE A6955
PHE A6985
ASN A6853
1.76A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_A_8NUA3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6wqf 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
SER A 254
ILE A 281
LEU A 262
LEU A 242
TYR A 209
1.72A20.77
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6wrh PEPTIDASE C16
(SARS-CoV-2)		5 / 12
SER A 245
THR A 301
PHE A 304
LEU A 178
VAL A 205
1.52A
None
GOL  A 508 (-3.8A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6wrh PEPTIDASE C16
(SARS-CoV-2)		5 / 12
SER A 239
VAL A 235
THR A 312
LEU A 199
PHE A 216
1.59A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_A_8NUA3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6wrh PEPTIDASE C16
(SARS-CoV-2)		5 / 12
SER A 103
SER A 262
THR A 301
ILE A 300
LEU A 289
1.53A23.37
None
None
GOL  A 508 (-3.8A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_A_8NUA3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6y2g REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
SER B 254
ILE B 281
LEU B 262
LEU B 242
TYR B 209
1.70A20.77
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_A_8NUA3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
SER A 254
ILE A 281
LEU A 262
LEU A 242
TYR A 209
1.69A17.30
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6yla LIGHT CHAIN
(Homo
sapiens)		5 / 12
SER C 165
VAL C 169
THR C 170
PHE C 145
VAL C 152
1.66A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_1
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6yla HEAVY CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		4 / 5
ASP B 107
ILE B  34
PHE B  29
ASN A 388
1.73A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6yla HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		5 / 12
SER H 184
THR L 178
LEU H 142
LEU H 163
VAL H 167
1.77A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6yla LIGHT CHAIN
(Homo
sapiens)		5 / 12
SER L 165
VAL L 169
THR L 170
PHE L 145
VAL L 152
1.64A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6yla HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		5 / 12
SER B 184
THR C 178
LEU B 142
LEU B 163
VAL B 167
1.78A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6yla LIGHT CHAIN
(Homo
sapiens)		5 / 12
SER C  99
TYR C 102
LEU C   4
LEU C  39
VAL C  29
1.74A
DMS  C 303 (-4.1A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6yla HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		5 / 12
VAL H 173
SER H 181
LEU L 181
LEU L 141
VAL L 139
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_A_8NUA3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
SER E 514
SER E 359
LEU E 387
PHE E 338
LEU E 368
1.79A17.23
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_A_8NUA3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6yla HEAVY CHAIN
LIGHT CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		5 / 12
SER H 103
SER L  33
PHE E 429
PHE E 464
TYR L  31
1.79A19.03
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6yla LIGHT CHAIN
(Homo
sapiens)		5 / 12
SER L  99
TYR L 102
LEU L   4
LEU L  39
VAL L  29
1.76A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6yla HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		5 / 12
VAL B 173
SER B 181
LEU C 181
LEU C 141
VAL C 139
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_1
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6yla HEAVY CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		4 / 5
ASP B 107
ILE B 102
ASN A 370
TYR B  32
1.73A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_1
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6yla HEAVY CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		4 / 5
ASP H 107
ILE H  34
PHE H  29
ASN E 388
1.69A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6ym0 LIGHT CHAIN
(Homo
sapiens)		5 / 12
SER L 165
VAL L 169
THR L 170
PHE L 145
VAL L 152
1.69A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6ym0 HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		5 / 12
VAL H 173
SER H 181
LEU L 181
LEU L 141
VAL L 139
1.53A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_1
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6ym0 HEAVY CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		4 / 5
ASP H 107
ILE H  34
PHE H  29
ASN E 388
1.76A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_A_8NUA3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6ynq REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
SER A 254
ILE A 281
LEU A 262
LEU A 242
TYR A 209
1.71A21.50
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6ynq REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
VAL A 204
THR A 199
PHE A 230
LEU A 262
VAL A 247
1.71A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6yor IGG L CHAIN
(Homo
sapiens)		5 / 12
SER L 165
VAL L 169
THR L 170
PHE L 145
VAL L 152
1.64A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6yor IGG H CHAIN
IGG L CHAIN
(Homo
sapiens)		5 / 12
VAL H 173
SER H 181
LEU L 181
LEU L 141
VAL L 139
1.53A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_A_8NUA3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
SER A 514
SER A 359
LEU A 387
PHE A 338
LEU A 368
1.79A17.02
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_A_8NUA3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6yor IGG H CHAIN
IGG L CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		5 / 12
SER H 103
SER L  33
PHE E 429
PHE E 464
TYR L  31
1.78A19.03
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_1
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6yor IGG H CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		4 / 5
ASP B 107
ILE B  34
PHE B  29
ASN A 388
1.69A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_A_8NUA3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
SER E 514
SER E 359
LEU E 387
PHE E 338
LEU E 368
1.80A17.02
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6yor IGG H CHAIN
IGG L CHAIN
(Homo
sapiens)		5 / 12
SER H 184
THR L 178
LEU H 142
LEU H 163
VAL H 167
1.77A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_A_8NUA3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6yor IGG H CHAIN
IGG L CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		5 / 12
SER B 103
SER C  33
PHE A 429
PHE A 464
TYR C  31
1.79A19.03
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6yor IGG L CHAIN
(Homo
sapiens)		5 / 12
SER L  99
TYR L 102
LEU L   4
LEU L  39
VAL L  29
1.75A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6yor IGG H CHAIN
IGG L CHAIN
(Homo
sapiens)		5 / 12
SER B 184
THR C 178
LEU B 142
LEU B 163
VAL B 167
1.77A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6yor IGG L CHAIN
(Homo
sapiens)		5 / 12
SER C  99
TYR C 102
LEU C   4
LEU C  39
VAL C  29
1.76A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6yor IGG L CHAIN
(Homo
sapiens)		5 / 12
SER C 165
VAL C 169
THR C 170
PHE C 145
VAL C 152
1.64A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_1
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6yor IGG H CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		4 / 5
ASP H 107
ILE H  34
PHE H  29
ASN E 388
1.69A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6yor IGG H CHAIN
IGG L CHAIN
(Homo
sapiens)		5 / 12
VAL B 173
SER B 181
LEU C 181
LEU C 141
VAL C 139
1.53A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_A_8NUA3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6yt8 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
SER A 254
ILE A 281
LEU A 262
LEU A 242
TYR A 209
1.71A21.50
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
TYR E  42
VAL E  36
LEU E  43
LEU E  75
VAL E  96
1.80A
None
None
None
EPE  E 203 (-3.6A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_1
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 5
ILE A 131
PHE A 132
ASN A  72
TYR A  42
1.76A
APR  A 201 (-3.1A)
APR  A 201 (-3.7A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_1
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 5
ILE C 131
PHE C 132
ASN C  72
TYR C  42
1.75A
APR  C 201 (-3.3A)
APR  C 201 (-3.5A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_1
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 5
ILE B 131
PHE B 132
ASN B  72
TYR B  42
1.77A
APR  B 201 (-3.2A)
APR  B 201 (-3.5A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
TYR C  42
VAL C  49
LEU C  43
LEU C  75
VAL C  96
1.69A
None
APR  C 201 (-3.6A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
TYR D  42
VAL D  49
LEU D  43
LEU D  75
VAL D  96
1.77A
None
APR  D 201 (-3.7A)
None
EDO  D 202 (-4.6A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_1
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 5
ASP C 162
ILE C 137
ASN B  72
TYR C 161
1.75A
None
None
None
EDO  C 203 (-4.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
TYR B  42
VAL B  49
LEU B  43
LEU B  75
VAL B  96
1.73A
None
APR  B 201 (-3.7A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
TYR E  42
VAL E  49
LEU E  43
LEU E  75
VAL E  96
1.77A
None
APR  E 201 (-3.7A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
TYR E  42
VAL E  36
LEU E  43
LEU E  75
VAL E  96
1.79A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		7btf NSP12
NSP8
(SARS-CoV-2)		5 / 12
SER A 384
VAL A 342
SER A 343
THR A 344
LEU B  95
1.75A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		7btf NSP12
(SARS-CoV-2)		5 / 12
VAL A 315
SER A 318
THR A 319
LEU A 308
LEU A 655
1.65A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_A_8NUA3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		7btf NSP12
(SARS-CoV-2)		5 / 12
SER A 318
THR A 319
LEU A 308
PHE A 326
LEU A 655
1.66A18.87
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_1
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		7btf NSP12
(SARS-CoV-2)		4 / 5
ILE A 171
PHE A 165
ASN A 781
TYR A 788
1.65A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		7btf NSP12
(SARS-CoV-2)		5 / 12
SER A 692
TYR A 689
VAL A 473
LEU A 638
LEU A 575
1.74A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_A_8NUA3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		7btf NSP12
NSP8
(SARS-CoV-2)		5 / 12
SER A 384
SER A 343
THR A 344
LEU B  95
LEU B  91
1.66A18.87
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_A_8NUA3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		7btf NSP12
(SARS-CoV-2)		5 / 12
SER A 709
ILE A 696
LEU A 775
PHE A 745
LEU A 723
1.58A18.87
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		7bv1 NSP7
(SARS-CoV-2)		5 / 12
VAL C  12
SER C  10
THR C   9
LEU C  20
VAL C  58
1.76A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_A_8NUA3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		7bv1 NSP12
(SARS-CoV-2)		5 / 12
SER A 318
THR A 319
LEU A 308
PHE A 326
LEU A 655
1.64A18.30
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		7bv1 NSP12
(SARS-CoV-2)		5 / 12
VAL A 315
SER A 318
THR A 319
LEU A 308
LEU A 655
1.67A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_A_8NUA3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		7bv1 NSP12
NSP8
(SARS-CoV-2)		5 / 12
SER A 384
SER A 343
THR A 344
LEU B  95
LEU B  91
1.78A18.30
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_A_8NUA3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		7bv2 NSP12
(SARS-CoV-2)		5 / 12
SER A 318
THR A 319
LEU A 308
PHE A 326
LEU A 655
1.68A18.30
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_A_8NUA3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		7bv2 NSP12
(SARS-CoV-2)		5 / 12
SER A 709
ILE A 696
LEU A 775
PHE A 745
LEU A 723
1.62A18.30
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		7bv2 NSP12
(SARS-CoV-2)		5 / 12
VAL A 315
SER A 318
THR A 319
LEU A 308
LEU A 655
1.61A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A93_B_8NUB3001_0
(5-HYDROXYTRYPTAMINE
RECEPTOR 2A,SOLUBLE
CYTOCHROME B562)		7bv2 NSP12
(SARS-CoV-2)		5 / 12
SER A 692
TYR A 689
VAL A 473
LEU A 638
LEU A 575
1.72A
None
U  T  12 ( 4.8A)
None
None
None